Target intelligence / Profile preview

Solute carrier family 25 member 47 pseudogene 1 (SLC25A47P1)

Target
SLC25A47P1
Molecular classification
Pseudogene, Other (not a receptor, transporter, enzyme, etc.)
01

Overview

Solute carrier family 25 member 47 pseudogene 1 (SLC25A47P1) is a **human pseudogene** located at chromosome 11q12.1, homologous to the functional gene SLC25A47 which encodes a mitochondrial carrier protein involved in liver metabolism and energy balance[4][1][7]. Pseudogenes like SLC25A47P1 are segments of DNA that resemble known genes but usually lack the ability to encode functional proteins due to disabling mutations or premature stop codons; they are not themselves therapeutic targets or active molecular entities in current drug discovery[8]. While some pseudogenes have been implicated as regulators of gene expression or disease modulators by acting as RNA decoys or microRNA sponges, there is **no direct evidence for SLC25A47P1 involvement in these processes**[2][8]. This molecule is generally annotated as "pseudogene" (molecular classification) and **should not be considered a canonical investigational target, receptor, transporter, enzyme, or biomarker**[1][4][7]. If your intent is to identify a therapeutic target, refer to the parent gene **solute carrier family 25 member 47 (SLC25A47)**, which is a mitochondrial transporter involved in hepatic energy homeostasis and is itself a potential drug target in liver disease[3][5]. SLC25A47P1 is currently only of interest in the context of genome studies, gene annotation, and potential regulatory non-coding RNA research.

Other names
SLC25A47P1HGNC:43860
02

Mechanism of action

Not applicable—no drugs or direct mechanisms of action described for SLC25A47P1

03

Biological functions

Likely non-functional in terms of direct biological activity (pseudogenes are generally transcriptionally silent or non-functional)Possible regulatory RNA decoy activity or influence on parent gene transcript levels, as observed for certain other pseudogenes, but no direct evidence for SLC25A47P1 specifically
04

Disease associations

None specifically attributed to SLC25A47P1.Some pseudogenes are implicated in regulatory functions related to cancer, but there is no direct data for SLC25A47P1 in disease roles
05

Safety considerations

Not applicable. Pseudogenes are not generally associated with specific safety or therapeutic risks unless misannotated as active genes in molecular assays
06

Interacting drugs

None reported—pseudogenes generally lack interacting drugs
07

Biomarkers

None reported—no validated biomarker utility for SLC25A47P1

Beyond the preview

Go deeper on Solute carrier family 25 member 47 pseudogene 1 (SLC25A47P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 25 member 47 pseudogene 1 (SLC25A47P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call